Summary
Bristol-Myers Squibb Company (BMY) announced a key addition to its Board of Directors, electing Michael R. McMullen as a new member effective July 1, 2024. This appointment increases the Board's size to eleven members. Mr. McMullen brings extensive executive leadership experience, notably as the former CEO of Agilent Technologies, where he significantly grew the company's market capitalization and drove operational and cultural transformations. His background in leading global operations and a proven track record of delivering shareholder returns are expected to be valuable assets to BMY. Furthermore, Mr. McMullen's expertise will be leveraged as he joins the Audit Committee of the Board. His compensation for board service aligns with the company's standard arrangements for non-employee directors, including an annual retainer and deferred share units. The company also noted the independence of Mr. McMullen under NYSE listing standards and its own board standards, with no disclosed arrangements or related party transactions influencing his appointment.
Key Highlights
- 1Michael R. McMullen elected to the Board of Directors, effective July 1, 2024.
- 2Board size increased to eleven members with Mr. McMullen's appointment.
- 3Mr. McMullen is a former CEO of Agilent Technologies with a strong track record in executive leadership and shareholder returns.
- 4His experience includes leading a significant transformation at Agilent, nearly tripling its market capitalization.
- 5Mr. McMullen will serve as a member of the Audit Committee.
- 6The company confirmed Mr. McMullen is independent under NYSE and Board standards.
- 7Standard compensation for non-employee directors will be provided, including an annual retainer and deferred share units.